CAM
PSTX

Crown Advisors Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Crown Advisors Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-150,000
Closed -$462K – 56
2023
Q1 		$462K Hold
150,000
– – 0.34% 48
2022
Q4 		$795K Hold
150,000
– – 0.72% 40
2022
Q3 		$529K Buy
+150,000
New +$496K 0.53% 41

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Crown Advisors Management's PSTX Position: Q2 2023 in Review

Crown Advisors Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2023, closing a stake of 150,000 shares — an estimated $462K sold.

Crown Advisors Management first reported a position in PSTX in Q3 2022 and held it in 3 quarters. The position peaked at $795K in Q4 2022. 94 funds tracked by Wall St. Rank hold PSTX as of Q2 2023.

  • Crown Advisors Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Crown Advisors Management sold 150,000 Poseida Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $462K.
  • Crown Advisors Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Crown Advisors Management's Poseida Therapeutics, Inc. Common Stock position peaked at $795K in Q4 2022.
  • 94 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Crown Advisors Management's 13F filing for Q2 2023, filed 14 Aug 2023.